Sign In
Buy LLY
$1,192.80
+22.94 (+1.96%)
At Close: Aug 06, 2026
These 3 Companies are Seeing Supercharged Sales Growth
12:31pm, Tuesday, 02'nd Sep 2025
The 2025 Q2 earnings season is now behind us, with the period largely positive and resilient. Throughout the period, these three companies posted notably strong sales growth.
Eli Lilly's New Drugs Beyond Mounjaro and Zepbound Boost Sales
11:06am, Tuesday, 02'nd Sep 2025
Eli Lilly's growing lineup beyond Mounjaro and Zepbound, including Omvoh and Jaypirca, is set to fuel revenue growth through 2025.
A Bad September to Remember? Time to Move to Safe Blue-Chip Dividend Stocks
05:42pm, Monday, 01'st Sep 2025
September has garnered a reputation as the worst month for stock market performance, supported by compelling historical data.
NVO's Wegovy vs. LLY's Tirzepatide: Who Leads in Heart Risk Reduction?
11:56am, Monday, 01'st Sep 2025
Novo Nordisk's Wegovy shows a stronger reduction in heart risks compared to Eli Lilly's tirzepatide in real-world data from the STEER study.
Cramer Loves These Dividend Stocks
09:31am, Monday, 01'st Sep 2025
Key Points Jim Cramer's Mad Money offers insights valuable to income investors, despite his broader focus on growth.
Novo's Wegovy Beats Lilly's Zepbound for Heart Health, Study Finds. What It Means for Stocks.
06:39am, Monday, 01'st Sep 2025
The study adds to growing evidence suggesting that the heart-protective benefits seen with Wegovy are specific to semaglutide.
Novo Nordisk Says Wegovy Cuts Heart Risk by 57% Compared With Eli Lilly's Obesity Drug
03:30am, Monday, 01'st Sep 2025
The study used evidence gathered from patient experiences rather than a controlled trial, Novo said.
Novo Nordisk's Wegovy cuts heart risk by 57% versus rival Lilly weight-loss drug in study
12:30pm, Sunday, 31'st Aug 2025
Novo Nordisk said on Sunday its blockbuster weight-loss drug Wegovy cut the risk of heart attack, stroke or death by 57% versus Eli Lilly's rival medicines Mounjaro and Zepbound in a real-world compar
Eli Lilly Is Proof That Wall Street Stars Don't Have To Be Tech Titans
01:44pm, Friday, 29'th Aug 2025
Although the stock has experienced its fair share of turbulence in 2025, Eli Lilly LLY is rapidly emerging as a key consideration for investors seeking to hedge their portfolios away from tech and AI
Eli Lilly joins forces with China tech giant to expand obesity drug market
06:04am, Friday, 29'th Aug 2025
Eli Lilly has partnered with a leading Chinese tech company, JD Health to fast-track its presence in China's rapidly expanding obesity drug market, boosting the company's global growth in the weight-l
Stock Of The Day: Another Breakout For Eli Lilly?
01:49pm, Thursday, 28'th Aug 2025
Trading is quiet in Eli Lilly and Co LLY on Thursday. The stock has stalled out at a resistance level.
Eli Lilly: Orals Unlock The Next Wave Of Obesity Drug Adoption
11:07am, Thursday, 28'th Aug 2025
Eli Lilly and Company's orforglipron shows strong efficacy and manufacturing advantages over Novo Nordisk's oral semaglutide, supporting future growth in the obesity and diabetes market. Orforglipron'
2 Growth Stocks That Could Be Worth $1 Trillion in 5 Years
09:45am, Thursday, 28'th Aug 2025
In 2018, Apple became the first publicly traded company to reach a $1 trillion market capitalization. Several more have joined that club since, but it remains highly exclusive, with fewer than 10 memb
Stevens Capital Closes Out Position in Eli Lilly
05:39am, Thursday, 28'th Aug 2025
According to a filing with the Securities and Exchange Commission dated Aug. 12, 2025, Stevens Capital Management LP completely exited its position in Eli Lilly and Company (LLY -0.20%), by selling al
Eli Lilly halts UK shipments of Mounjaro diabetes and weight-loss drug
04:14am, Thursday, 28'th Aug 2025
Eli Lilly and Co (NYSE:LLY) has halted shipments of its Mounjaro diabetes and weight-loss drug to the UK ahead of a planned price hike next month. Earlier this week the US drug giant warned against "
